Chinese General Practice ›› 2025, Vol. 28 ›› Issue (22): 2791-2797.DOI: 10.12114/j.issn.1007-9572.2024.0488
• Original Research·Focus on Body Index and Health Relationship • Previous Articles
Received:
2024-09-15
Revised:
2025-01-11
Published:
2025-08-05
Online:
2025-06-30
Contact:
MA Qing
通讯作者:
马清
作者简介:
作者贡献:
石小天负责研究的设计与实施、数据处理及统计分析、结果关键性解释及论文撰写;王珊、杨华昱负责研究的设计、数据质量控制及论文修改;杨一帆、李旭负责资料的收集整理;马清负责论文的修改与最终版本修订、对文章整体负责。
基金资助:
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0488
项目 | 低体重组(n=18) | 正常体重组(n=221) | 超重组(n=273) | 肥胖组(n=87) | 检验统计量值 | P值 |
---|---|---|---|---|---|---|
年龄[M(P25,P75),岁] | 81.0(73.5,83.0) | 78.0(74.0,84.0) | 76.0(70.0,82.0) | 77.00(69.0,82.0) | 7.24 | 0.065 |
白细胞[M(P25,P75),×109/L] | 6.07(4.40,6.53) | 5.88(5.02,6.86) | 6.17(5.34,7.30) | 6.91(6.05,7.63) | 27.96 | <0.001 |
血红蛋白[M(P25,P75),g/L] | 132.50(126.50,140.75) | 138.00(129.00,149.00) | 145.00(135.00,153.00) | 144.00(133.50,152.00) | 27.65 | <0.001 |
白蛋白[M(P25,P75),g/L] | 46.10(43.00,46.52) | 46.00(43.80,47.60) | 45.70(44.05,47.60) | 45.55(44.20,46.88) | 0.85 | 0.837 |
丙氨酸氨基转移酶[M(P25,P75),U/L] | 13.50(11.25,14.75) | 15.00(11.00,19.00) | 18.00(13.00,22.00) | 19.00(14.00,25.50) | 38.31 | <0.001 |
天冬氨酸氨基转移酶[M(P25,P75),U/L] | 21.00(19.00,24.00) | 20.00(17.00,23.00) | 20.00(18.00,23.00) | 21.00(17.00,25.00) | 1.32 | 0.726 |
糖化血红蛋白[M(P25,P75),%] | 5.55(5.20,5.80) | 5.60(5.30,5.90) | 5.70(5.40,6.20) | 5.90(5.60,6.50) | 35.73 | <0.001 |
葡萄糖[M(P25,P75),mmol/L] | 5.94(5.39,6.50) | 5.91(5.58,6.28) | 6.16(5.70,6.78) | 6.27(5.81,7.18) | 21.54 | <0.001 |
总胆固醇[M(P25,P75),mmol/L] | 5.38(4.78,5.45) | 4.75(4.12,5.30) | 4.64(3.93,5.30) | 4.49(3.91,5.14) | 9.67 | 0.022 |
三酰甘油[M(P25,P75),mmol/L] | 0.80(0.63,1.07) | 1.02(0.78,1.39) | 1.27(0.95,1.73) | 1.35(1.10,1.69) | 58.25 | <0.001 |
高密度脂蛋白[M(P25,P75),mmol/L] | 1.69(1.53,2.02) | 1.40(1.12,1.69) | 1.13(1.00,1.30) | 1.10(0.94,1.25) | 94.96 | <0.001 |
低密度脂蛋白[M(P25,P75),mmol/L] | 2.92(2.52,3.37) | 2.79(2.24,3.37) | 2.85(2.30,3.54) | 2.78(2.31,3.32) | 2.29 | 0.514 |
尿素氮[M(P25,P75),mmol/L] | 5.67(5.19,6.62) | 5.83(4.80,7.05) | 5.68(4.77,7.00) | 5.95(5.09,7.26) | 1.48 | 0.686 |
肌酐[M(P25,P75),μmol/L] | 75.90(69.45,80.20) | 76.10(66.70,89.40) | 81.70(71.90,94.60) | 83.70(73.50,92.35) | 17.91 | <0.001 |
尿酸[M(P25,P75),μmol/L] | 283.55(268.77,394.85) | 322.50(263.00,378.30) | 350.70(303.70,405.80) | 372.80(323.35,433.40) | 34.50 | <0.001 |
死亡[例(%)] | 11(61.1) | 58(26.2) | 63(23.1) | 26(29.9) | 13.27a | 0.004 |
男性[例(%)] | 10(55.6) | 163(73.8) | 227(83.2) | 77(88.5) | 17.45a | <0.001 |
高血压[例(%)] | 3(16.7) | 101(45.7) | 149(54.6) | 52(59.8) | 15.05a | 0.002 |
糖尿病[例(%)] | 4(22.2) | 38(17.2) | 52(19.0) | 22(25.3) | 2.73a | 0.435 |
高脂血症[例(%)] | 6(33.3) | 90(40.7) | 149(54.6) | 40(46.0) | 11.08a | 0.011 |
冠心病[例(%)] | 4(22.2) | 65(29.4) | 99(36.3) | 31(35.6) | 3.79a | 0.285 |
脑血管病[例(%)] | 2(11.1) | 48(21.7) | 55(20.2) | 18(20.7) | 1.20a | 0.754 |
慢性肺疾病[例(%)] | 4(22.2) | 52(23.5) | 56(20.5) | 19(21.8) | 0.65a | 0.885 |
恶性肿瘤[例(%)] | 3(16.7) | 40(18.1) | 43(15.8) | 20(23.0) | 2.32a | 0.507 |
Table 1 Baseline characteristics of participants
项目 | 低体重组(n=18) | 正常体重组(n=221) | 超重组(n=273) | 肥胖组(n=87) | 检验统计量值 | P值 |
---|---|---|---|---|---|---|
年龄[M(P25,P75),岁] | 81.0(73.5,83.0) | 78.0(74.0,84.0) | 76.0(70.0,82.0) | 77.00(69.0,82.0) | 7.24 | 0.065 |
白细胞[M(P25,P75),×109/L] | 6.07(4.40,6.53) | 5.88(5.02,6.86) | 6.17(5.34,7.30) | 6.91(6.05,7.63) | 27.96 | <0.001 |
血红蛋白[M(P25,P75),g/L] | 132.50(126.50,140.75) | 138.00(129.00,149.00) | 145.00(135.00,153.00) | 144.00(133.50,152.00) | 27.65 | <0.001 |
白蛋白[M(P25,P75),g/L] | 46.10(43.00,46.52) | 46.00(43.80,47.60) | 45.70(44.05,47.60) | 45.55(44.20,46.88) | 0.85 | 0.837 |
丙氨酸氨基转移酶[M(P25,P75),U/L] | 13.50(11.25,14.75) | 15.00(11.00,19.00) | 18.00(13.00,22.00) | 19.00(14.00,25.50) | 38.31 | <0.001 |
天冬氨酸氨基转移酶[M(P25,P75),U/L] | 21.00(19.00,24.00) | 20.00(17.00,23.00) | 20.00(18.00,23.00) | 21.00(17.00,25.00) | 1.32 | 0.726 |
糖化血红蛋白[M(P25,P75),%] | 5.55(5.20,5.80) | 5.60(5.30,5.90) | 5.70(5.40,6.20) | 5.90(5.60,6.50) | 35.73 | <0.001 |
葡萄糖[M(P25,P75),mmol/L] | 5.94(5.39,6.50) | 5.91(5.58,6.28) | 6.16(5.70,6.78) | 6.27(5.81,7.18) | 21.54 | <0.001 |
总胆固醇[M(P25,P75),mmol/L] | 5.38(4.78,5.45) | 4.75(4.12,5.30) | 4.64(3.93,5.30) | 4.49(3.91,5.14) | 9.67 | 0.022 |
三酰甘油[M(P25,P75),mmol/L] | 0.80(0.63,1.07) | 1.02(0.78,1.39) | 1.27(0.95,1.73) | 1.35(1.10,1.69) | 58.25 | <0.001 |
高密度脂蛋白[M(P25,P75),mmol/L] | 1.69(1.53,2.02) | 1.40(1.12,1.69) | 1.13(1.00,1.30) | 1.10(0.94,1.25) | 94.96 | <0.001 |
低密度脂蛋白[M(P25,P75),mmol/L] | 2.92(2.52,3.37) | 2.79(2.24,3.37) | 2.85(2.30,3.54) | 2.78(2.31,3.32) | 2.29 | 0.514 |
尿素氮[M(P25,P75),mmol/L] | 5.67(5.19,6.62) | 5.83(4.80,7.05) | 5.68(4.77,7.00) | 5.95(5.09,7.26) | 1.48 | 0.686 |
肌酐[M(P25,P75),μmol/L] | 75.90(69.45,80.20) | 76.10(66.70,89.40) | 81.70(71.90,94.60) | 83.70(73.50,92.35) | 17.91 | <0.001 |
尿酸[M(P25,P75),μmol/L] | 283.55(268.77,394.85) | 322.50(263.00,378.30) | 350.70(303.70,405.80) | 372.80(323.35,433.40) | 34.50 | <0.001 |
死亡[例(%)] | 11(61.1) | 58(26.2) | 63(23.1) | 26(29.9) | 13.27a | 0.004 |
男性[例(%)] | 10(55.6) | 163(73.8) | 227(83.2) | 77(88.5) | 17.45a | <0.001 |
高血压[例(%)] | 3(16.7) | 101(45.7) | 149(54.6) | 52(59.8) | 15.05a | 0.002 |
糖尿病[例(%)] | 4(22.2) | 38(17.2) | 52(19.0) | 22(25.3) | 2.73a | 0.435 |
高脂血症[例(%)] | 6(33.3) | 90(40.7) | 149(54.6) | 40(46.0) | 11.08a | 0.011 |
冠心病[例(%)] | 4(22.2) | 65(29.4) | 99(36.3) | 31(35.6) | 3.79a | 0.285 |
脑血管病[例(%)] | 2(11.1) | 48(21.7) | 55(20.2) | 18(20.7) | 1.20a | 0.754 |
慢性肺疾病[例(%)] | 4(22.2) | 52(23.5) | 56(20.5) | 19(21.8) | 0.65a | 0.885 |
恶性肿瘤[例(%)] | 3(16.7) | 40(18.1) | 43(15.8) | 20(23.0) | 2.32a | 0.507 |
变量 | β | SE | Z值 | P值 | HR(95%CI) |
---|---|---|---|---|---|
年龄 | 0.15 | 0.01 | 12.17 | <0.001 | 1.16(1.14~1.19) |
BMI | -0.03 | 0.02 | -1.21 | 0.228 | 0.97(0.92~1.02) |
收缩压 | 0.01 | 0.00 | 2.39 | 0.017 | 1.01(1.01~1.02) |
舒张压 | -0.03 | 0.01 | -4.74 | <0.001 | 0.97(0.95~0.98) |
白细胞 | 0.12 | 0.05 | 2.29 | 0.022 | 1.12(1.02~1.24) |
血红蛋白 | -0.03 | 0.01 | -5.51 | <0.001 | 0.97(0.96~0.98) |
丙氨酸氨基转移酶 | -0.02 | 0.01 | -1.98 | 0.048 | 0.98(0.96~0.99) |
天冬氨酸氨基转移酶 | 0 | 0.01 | -0.35 | 0.725 | 1.00(0.97~1.02) |
糖化血红蛋白 | 0.23 | 0.07 | 3.09 | 0.002 | 1.26(1.09~1.46) |
葡萄糖 | 0.12 | 0.04 | 3.14 | 0.002 | 1.13(1.05~1.22) |
总胆固醇 | -0.05 | 0.09 | -0.62 | 0.534 | 0.95(0.80~1.12) |
三酰甘油 | -0.18 | 0.13 | -1.37 | 0.169 | 0.84(0.65~1.08) |
高密度脂蛋白 | 0.12 | 0.22 | 0.58 | 0.563 | 1.13(0.74~1.73) |
低密度脂蛋白 | -0.07 | 0.10 | -0.69 | 0.488 | 0.93(0.77~1.13) |
肌酐 | 0.02 | 0.00 | 5.29 | <0.001 | 1.02(1.01~1.02) |
BMI | |||||
肥胖组 | 0.14 | 0.24 | 0.58 | 0.560 | 1.15(0.72~1.84) |
超重组 | -0.15 | 0.18 | -0.80 | 0.425 | 0.86(0.61~1.24) |
低体重组 | 1.09 | 0.33 | 3.31 | <0.001 | 2.97(1.56~5.66) |
女性 | -0.14 | 0.21 | -0.68 | 0.496 | 0.87(0.58~1.30) |
高血压 | 0.13 | 0.16 | 0.81 | 0.421 | 1.14(0.83~1.56) |
糖尿病 | 0.25 | 0.19 | 1.32 | 0.188 | 1.28(0.89~1.86) |
高脂血症 | -0.20 | 0.16 | -1.23 | 0.219 | 0.82(0.60~1.12) |
冠心病 | 0.06 | 0.17 | 0.36 | 0.720 | 1.06(0.76~1.48) |
脑血管病 | -0.03 | 0.20 | -0.15 | 0.884 | 0.97(0.66~1.43) |
慢性肺疾病 | 0.29 | 0.18 | 2.74 | 0.098 | 1.34(0.95~1.92) |
恶性肿瘤 | 0.97 | 0.17 | 32.62 | <0.001 | 2.64(1.89~3.69) |
Table 2 The results of univariate Cox regression
变量 | β | SE | Z值 | P值 | HR(95%CI) |
---|---|---|---|---|---|
年龄 | 0.15 | 0.01 | 12.17 | <0.001 | 1.16(1.14~1.19) |
BMI | -0.03 | 0.02 | -1.21 | 0.228 | 0.97(0.92~1.02) |
收缩压 | 0.01 | 0.00 | 2.39 | 0.017 | 1.01(1.01~1.02) |
舒张压 | -0.03 | 0.01 | -4.74 | <0.001 | 0.97(0.95~0.98) |
白细胞 | 0.12 | 0.05 | 2.29 | 0.022 | 1.12(1.02~1.24) |
血红蛋白 | -0.03 | 0.01 | -5.51 | <0.001 | 0.97(0.96~0.98) |
丙氨酸氨基转移酶 | -0.02 | 0.01 | -1.98 | 0.048 | 0.98(0.96~0.99) |
天冬氨酸氨基转移酶 | 0 | 0.01 | -0.35 | 0.725 | 1.00(0.97~1.02) |
糖化血红蛋白 | 0.23 | 0.07 | 3.09 | 0.002 | 1.26(1.09~1.46) |
葡萄糖 | 0.12 | 0.04 | 3.14 | 0.002 | 1.13(1.05~1.22) |
总胆固醇 | -0.05 | 0.09 | -0.62 | 0.534 | 0.95(0.80~1.12) |
三酰甘油 | -0.18 | 0.13 | -1.37 | 0.169 | 0.84(0.65~1.08) |
高密度脂蛋白 | 0.12 | 0.22 | 0.58 | 0.563 | 1.13(0.74~1.73) |
低密度脂蛋白 | -0.07 | 0.10 | -0.69 | 0.488 | 0.93(0.77~1.13) |
肌酐 | 0.02 | 0.00 | 5.29 | <0.001 | 1.02(1.01~1.02) |
BMI | |||||
肥胖组 | 0.14 | 0.24 | 0.58 | 0.560 | 1.15(0.72~1.84) |
超重组 | -0.15 | 0.18 | -0.80 | 0.425 | 0.86(0.61~1.24) |
低体重组 | 1.09 | 0.33 | 3.31 | <0.001 | 2.97(1.56~5.66) |
女性 | -0.14 | 0.21 | -0.68 | 0.496 | 0.87(0.58~1.30) |
高血压 | 0.13 | 0.16 | 0.81 | 0.421 | 1.14(0.83~1.56) |
糖尿病 | 0.25 | 0.19 | 1.32 | 0.188 | 1.28(0.89~1.86) |
高脂血症 | -0.20 | 0.16 | -1.23 | 0.219 | 0.82(0.60~1.12) |
冠心病 | 0.06 | 0.17 | 0.36 | 0.720 | 1.06(0.76~1.48) |
脑血管病 | -0.03 | 0.20 | -0.15 | 0.884 | 0.97(0.66~1.43) |
慢性肺疾病 | 0.29 | 0.18 | 2.74 | 0.098 | 1.34(0.95~1.92) |
恶性肿瘤 | 0.97 | 0.17 | 32.62 | <0.001 | 2.64(1.89~3.69) |
变量 | 模型1 | 模型2 | 模型3 | 模型4 | ||||
---|---|---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
BMI分组 | ||||||||
正常体重组 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
低体重组 | 2.97(1.56~5.66) | <0.001 | 2.60(1.36~4.96) | 0.006 | 2.60(1.32~5.13) | 0.006 | 2.76(1.37~5.55) | 0.004 |
超重组 | 0.86(0.61~1.24) | 0.425 | 0.94(0.63~1.40) | 0.763 | 0.94(0.63~1.40) | 0.763 | 0.95(0.63~1.43) | 0.819 |
肥胖组 | 1.15(0.72~1.84) | 0.560 | 1.15(0.68~1.93) | 0.603 | 1.15(0.68~1.93) | 0.603 | 1.03(0.61~1.76) | 0.901 |
Table 3 Relationship between BMI groups and all-cause mortality in different models
变量 | 模型1 | 模型2 | 模型3 | 模型4 | ||||
---|---|---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
BMI分组 | ||||||||
正常体重组 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
低体重组 | 2.97(1.56~5.66) | <0.001 | 2.60(1.36~4.96) | 0.006 | 2.60(1.32~5.13) | 0.006 | 2.76(1.37~5.55) | 0.004 |
超重组 | 0.86(0.61~1.24) | 0.425 | 0.94(0.63~1.40) | 0.763 | 0.94(0.63~1.40) | 0.763 | 0.95(0.63~1.43) | 0.819 |
肥胖组 | 1.15(0.72~1.84) | 0.560 | 1.15(0.68~1.93) | 0.603 | 1.15(0.68~1.93) | 0.603 | 1.03(0.61~1.76) | 0.901 |
变量 | 模型1 | 模型2 | 模型3 | 模型4 | ||||
---|---|---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
BMI | ||||||||
正常体重组 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
低体重组 | 5.71(2.23~14.60) | <0.001 | 4.95(1.93~12.69) | <0.001 | 5.95(2.13~16.56) | <0.001 | 5.55(1.83~16.78) | 0.002 |
超重组 | 0.70(0.34~1.43) | 0.328 | 0.90(0.44~1.86) | 0.776 | 0.47(0.21~1.06) | 0.069 | 0.51(0.22~1.19) | 0.119 |
肥胖组 | 1.33(0.57~3.12) | 0.505 | 1.76(0.74~4.16) | 0.198 | 0.83(0.30~2.36) | 0.733 | 0.98(0.33~2.91) | 0.977 |
Table 4 Relationship between BMI groups and death from cardiovascular causes in different models
变量 | 模型1 | 模型2 | 模型3 | 模型4 | ||||
---|---|---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
BMI | ||||||||
正常体重组 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
低体重组 | 5.71(2.23~14.60) | <0.001 | 4.95(1.93~12.69) | <0.001 | 5.95(2.13~16.56) | <0.001 | 5.55(1.83~16.78) | 0.002 |
超重组 | 0.70(0.34~1.43) | 0.328 | 0.90(0.44~1.86) | 0.776 | 0.47(0.21~1.06) | 0.069 | 0.51(0.22~1.19) | 0.119 |
肥胖组 | 1.33(0.57~3.12) | 0.505 | 1.76(0.74~4.16) | 0.198 | 0.83(0.30~2.36) | 0.733 | 0.98(0.33~2.91) | 0.977 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
王友发,孙明晓,薛宏,等. 《中国肥胖预防和控制蓝皮书》解读及中国肥胖预防控制措施建议[J]. 中华预防医学杂志,2019,53(9):875-884. DOI:10.3760/cma.j.issn.0253?9624.2019.09.003.
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[1] | YU Wenhua, LI Jianguo, DUAN Wenyan, GAO Xuyan, LI Xiaxia, ZHANG Zilong, ZHANG Li, MA Lina. Reliability and Validity of the Function Impairment Screening Tool among Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(24): 3000-3004. |
[2] | YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058. |
[3] | WANG Rupeng, NAN Jing, HU Yiran, YANG Shenghua, JIN Zening. Predictive Value of the Triglyceride-Glucose Body Mass Index for Slow Flow/No-reflow Phenomenon in Patients with Type 2 Diabetes Mellitus and Acute Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention [J]. Chinese General Practice, 2025, 28(24): 2985-2992. |
[4] | LI Jiaxin, LIU Zhonghui, XIE Shuo, FU Zhifang, SUN Dan, JIAO Hongmei. Trajectory in Biomarkers of Metabolic and Inflammatory States as Early Predictors of Chronic Critical Illness in Aging Patients [J]. Chinese General Practice, 2025, 28(24): 2993-2999. |
[5] | WEI Yunhong, YANG Li, WANG Yulu, YE Qiufang, DAI Anni, HE Yan. Study on Cardiopulmonary Function During Different Exercise Stages in Patients with Obesity-related Hypertension [J]. Chinese General Practice, 2025, 28(24): 2972-2978. |
[6] | ZHAO Xiaoqing, GUO Tongtong, ZHANG Xinyi, LI Linhong, ZHANG Ya, JI Lihong, DONG Zhiwei, GAO Qianqian, CAI Weiqing, ZHENG Wengui, JING Qi. Construction and Validation of a Risk Prediction Model for Cognitive Impairment in Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(22): 2776-2783. |
[7] | WANG Shuang, WU Shufa, LING Yao, TAN Xiwei, CAO Rudai, ZENG Huiting, KONG Danli, DING Yuanlin, YU Haibing. Metabolomics Based Mediating Role of Non-lipid Metabolites in the Relationship between Obesity and Diabetic Retinopathy: a Mendelian Randomization Study [J]. Chinese General Practice, 2025, 28(21): 2625-2634. |
[8] | LIANG Hengmiao, HUANG Sizhe, CHEN Yuting, LIU Ce, WANG Huijun, DU Qingfeng. A Retrospective Analysis of the Association between Serum Uric Acid Levels and Insulin Resistance Degrees in Individuals Undergoing Health Examination [J]. Chinese General Practice, 2025, 28(21): 2635-2642. |
[9] | JIN Yan, YANG Yang, WANG Lulu, ZHENG Qingwan, LI Xinyan, ZHANG Ning. Effects of Exercise Training after Bariatric Surgery on Cardiopulmonary Function in Patients with Type 2 Diabetes Mellitus and Obesity: a Randomized Controlled Trial [J]. Chinese General Practice, 2025, 28(21): 2611-2617. |
[10] | LI Chunxian, LIU Annuo. Study on the Effect and Predictive Value of Obesity and Lipid-related Indices on Metabolic Syndrome in Adults [J]. Chinese General Practice, 2025, 28(21): 2595-2603. |
[11] | HAO Aihua, ZENG Ziying, JIN Aiqiong, TANG Lingling, ZHENG Zique, MA Jingtai, ZHAO Jianguo, ZENG Weilin, XIAO Jianpeng, NIE Hui, YANG Ying. Analysis of Factors Influencing Avoidable Hospitalization for Elderly Hypertensive Patients [J]. Chinese General Practice, 2025, 28(19): 2370-2375. |
[12] | PAN Yaojia, FU Fanglin, HAN Zheng, SUN Meng, GU Huaicong, WANG Weiqiang. Correlation of the Type of Obesity with the Cardiometabolic Multimorbidity: a Study in Male and Female Middle-aged Residents in Anhui Province [J]. Chinese General Practice, 2025, 28(18): 2285-2293. |
[13] | CHEN Qiaoqiao, SU Ping, ZHAO Yingying, PANG Jinhong, SHI Jie, WANG Yaqian, LI Qiuchun, HE Ruiyan, WANG Yue, CHEN Xueyu, QIAO Junpeng, CHI Weiwei. Association between Triglyceride-Glucose Index and Incident Cardiometabolic Multimorbidity in the Elderly: a Prospective Cohort Study [J]. Chinese General Practice, 2025, 28(18): 2270-2277. |
[14] | JIANG Xiaoman, XU Xinyi, DING Lingyu, GUO Yinning, MIAO Xueyi, CHEN Li, XU Qin. Clinical Characteristics and Correlation between Preoperative Frailty and Metabolic Syndrome among Older Patients with Gastric Cancer [J]. Chinese General Practice, 2025, 28(17): 2134-2141. |
[15] | WANG Biqing, ZHANG Ping, YANG Hongxia, WANG Qian, JU Chunxiao, ZHAO Junnan, MEI Jun, ZHANG Ying, XU Fengqin. Meta-analysis of Prevalence and Development Trend of Mild Cognitive Impairment in Elderly Hypertensive Patients in China [J]. Chinese General Practice, 2025, 28(17): 2186-2192. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||